Skip to content

Service 05 / 05

Licensing & Partnerships.

In-licensing, out-licensing and distribution partnerships for real markets.

We in-license products for Europe, out-license our own brands and portfolio assets, and structure distribution partnerships for selected Latin American markets with a clear evaluation and term process. Every arrangement is built on the same quality and regulatory infrastructure that supports Nervinetten®, EMASEX® and Zellaforte®.

Our approach

Structured evaluation, then a clear term process.

We assess fit against category, regulatory route, channel and quality requirements before commercial terms are discussed. That order avoids the common failure mode of agreeing terms for a product that cannot legally be sold as intended.

As both a licensor and a licensee, we understand the asymmetries on each side — and we write agreements that survive an audit as well as a negotiation.

Two pharmaceutical specialists reviewing partnership documentation together

What you get.

Concrete deliverables — not a strategy deck that dies in a drawer.

  1. Asset evaluation

    Category, regulatory route, competitive position and channel fit assessed before terms.

  2. In-licensing

    We take on products for Europe or selected Latin American markets under a defined territorial and channel scope.

  3. Out-licensing

    Our own brands and portfolio assets licensed into markets we do not serve directly.

  4. Distribution agreements

    Terms, minimums, quality annexes and exit provisions defined in writing.

  5. Quality annex

    Responsibilities allocated explicitly between the parties, aligned to GMP/GDP scope.

  6. Transition management

    Handover of documentation, registration and stock without a gap in supply.

Built for.

Three situations where this service pays for itself.

  • Portfolio owners

    You hold rights you cannot commercialise locally and want a partner who carries the operating risk.

  • Regional operators

    You want documented European or Latin American assets for your market and need a licensor with clear responsibilities.

  • Strategic exits

    You are divesting a product line and need an orderly transition rather than a fire sale.

Common questions.

Straight answers — the rest we cover on a call.

What categories do you in-license?

Pharmaceuticals, OTC and consumer health with a clear regulatory route and defensible pharmacy, specialist or partner-channel fit in the agreed market.

Are your own brands available for licensing?

Selected territories and channels, yes. We discuss availability case by case, with the quality documentation available up front.

How do you structure terms?

After the evaluation phase. Territory, channel, minimums, duration and quality responsibilities are fixed in writing before any commercial launch activity.

Have an asset — or want one?

Tell us which side of the table you are on, the product and the target territory.

Start a licensing discussion

Services are scoped to the product, territory and responsibilities agreed with AFZ and qualified partners. National authorisations, MAH roles and reimbursement pathways apply only where legally applicable and explicitly mandated.

Partner with AFZ

Licensing & partnership enquiry

Your enquiry What would you like to discuss?

Choose the closest match. Your selection routes the enquiry and changes the details we ask for.

Opportunity details Give us the useful context.

Complete the section that matches the enquiry type you selected.

AFZ product and territory

Product offered to AFZ

Market-access brief

Documents requested

Your message What should we know before we reply?

A concise summary of the opportunity, timing and desired next step is enough.

Contact details Where should we reply?

We use these details only to assess and answer this enquiry.

By sending, you agree to our privacy policy. We use these details only to assess and answer your enquiry.